{"id":3525,"date":"2022-09-05T19:21:03","date_gmt":"2022-09-05T19:21:03","guid":{"rendered":"https:\/\/palynziqhcp-dev-001.azurewebsites.net\/en-us\/palynziq\/?page_id=3525"},"modified":"2024-06-12T13:47:52","modified_gmt":"2024-06-12T13:47:52","slug":"safety-profile-video","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/safety-profile-video\/","title":{"rendered":"Safety Profile – Video"},"content":{"rendered":"
For Healthcare Professionals<\/small><\/p>\n
Safety<\/strong><\/p>\n Dr. Barbara Burton and Heather Bausell, RD, LDN, provide a detailed overview of PALYNZIQ\u2019s safety profile, including data showing how the rates of the 3 most common adverse reactions decrease from induction\/titration to maintenance, regardless of the specific maintenance dose (20 mg, 40 mg, or 60 mg).<\/p>\n Indication<\/strong><\/p>\n PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol\/L on existing management.<\/p>\n Please see full Prescribing Information<\/a>, with Boxed Warning for risk of anaphylaxis, and Medication Guide, here.<\/a><\/strong><\/p>\n